→ Another day, another gene therapy developer. Prevail Therapeutics, which leapt out of stealth mode in 2017 and raised $75 million in a Series A last year for its disease-modifying approach to neurodegenerative diseases, has secured another $5o million in the bank. The New York-based company is run by Columbia University’s Asa Abeliovich, who helped co-found Alector, which is going after Alzheimer’s.
→ Founded at the University of Basel and spun off in 2014, Swiss autoimmune-focused firm Polyneuron Pharmaceuticals has scored 22.5 million swiss francs (about $22.6 million) in Series A financing, led by Sofinnova Partners and New Enterprise Associates (NEA). The injection will be used to conduct the first human trial of its lead drug, PN-1007, for a rare nervous system disease called anti-MAG neuropathy, as well as to shepherd three other programs through preclinical development.
→ With dual expertise in material science and biological engineering, Darrell Irvine of MIT has helped launch the T cell therapy startup Torque Therapeutics. He’s now pioneering another tumor fighting approach Elicio Therapeutics, a startup born out of the ashes of a generation of failed cancer vaccines. The Cambridge, MA-based company uses an amphiphile platform to precisely deliver immunogens to the lymphatic system, it says, thereby “orchestrating” an immune response to aggressive cancers. Launching with $30 million in funding, Elicio plans to begin human studies in pancreatic, colorectal and head and neck cancers in the first half of 2020.
→ In another nod to real world data and artificial intelligence — buzzwords that are taking an evident, if vague, hold of the industry — Bristol-Myers Squibb has inked an agreement to integrate a platform created by Concerto HealthAI into its clinical development process. The pact focuses on precision oncology.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription